Industry News prev next
Jun 26 2006
New FDA Approval for Lumigan
June 23, 2006. The FDA today approved Allergan’s glaucoma medication, Lumigan (bimatoprost ophthalmic solution, .03%), for first-line treatment for elevated intraocular pressure associated with ocular hypertension or open angle glaucoma.
In 2001, the FDA approved Lumigan as an IOP reducing pharmaceutical for second-line use in patients who were intolerant or did not have sufficient IOP reduction from other IOP lowering pharmaceuticals.
This ruling supports the use of Lumigan as an initial treatment option, as well as its continued utilization at other times in the disease process.
To read more about this, click on the link to the Allergan website: Allergan
